Management of HTN in diabetic patient Fatemeh saffarian Assisstant professor of cardiology at qazvin university of medicine.

Slides:



Advertisements
Similar presentations
JNC 8 Guidelines….
Advertisements

Making Sense of the New Guidelines: Hypertension The More We Learn, the Less We Know Zeb K. Henson, M.D. Assistant Professor, Department of Medicine &
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
CVD risk estimation and prevention: An overview of SIGN 97.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Hypertension Guidelines 2014
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Blood Pressure Monitoring
Hypertension: what is new…and old GREG FOTIEO, MD.
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
Hypertension: JNC 7 Guidelines Steven W Harris MHS PA-C.
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
HOME AND AMBULATORY BLOOD PRESSURE MONITORING
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
DR. IDOWU AKOLADE EDM DIVISION LUTH
1 1 Individualized Therapy forHypertension Introduction to Primary Care: a course of the Center of Post Graduate Studies in FM PO Box – Riyadh
ACUTE STROKE — Hypertension is a common problem in patients with both type 1 and type 2 diabetes but the time course in relation to the duration.
0CTOBER 2010 An Approach for Sub-Saharan Africa. Dr. Linda Hawker, MD, CCFP General Practice Kelowna BC Canada.
1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
 Update on Hypertension Troy L. Randle, DO, FACC, FACOI.
Hypertension Guidelines 2015 Barry D. Bertolet, MD Cardiology Associates of North Mississippi Tupelo – Columbus – Starkville - Oxford.
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
Blood pressure control in primary health care WORKSHOP
DION GALLANT, MD PRIMARY CARE SERVICE LINE MEDICAL DIRECTOR PRESBYTERIAN MEDICAL GROUP JNC 8.
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
1 Current & New treatment strategies to address CV Risk.
-Greatest Achievements in Endocrinology – Jose Mario F. de Oliveira, MD, Ph.D. -Brigham&Womens Hospital – Endocrinology, Hypertension&Diabetes Division.
Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.
Hypertension Mohammad Garakyaraghi,MD Cardiologist Associate Professor.
Thiazide-Like/Calcium Channel Blocker (CCB) Agents: A Major Combination for Hypertension Management Safar M, Blacher J. Am J Cardiovasc Drugs. 2014; DOI.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
PHARMACOTHERAPY OF HYPERTENSION Based on New Guidelines Fariborz Nikaeen; MD Interventional cardiologist 2 november 2015.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
CONTROL OF HYPERTENTION IN SPECIAL GROUPS. HYPERTENTION IN PREGNANCY.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
2007 Hypertension as a Public Health Risk January, 2007.
Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
HTN & CKD 1. HTN has been reported to occur in 85-95% of patients with CKD (stages 3–5). The relationship between HTN & CKD is cyclic in nature. Uncontrolled.
April 22, 2016 Connie Tien Daniel Kim Jeffrey Hughes Michelle Di Fiore
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Managing Blood Pressure in the Older Adult Jamie McCarrell, Pharm.D., BCPS, CGP TTUHSC School of Pharmacy.
Management of progression of CKD 순천향 대학병원 신장내과 강혜란.
David Antecol, M.D., FACC, FASH, FRCP(C) Specialist in Clinical Hypertension (American Society of Hypertension) Disclosures: None.
Hypertension guidelines What’s all the controversy about 2015
JNC VIII Hypertension.
Hypertension JNC VIII Guidelines.
Hypertension Guidelines-JNC 8
What’s New in the 2013 ESC/ESH Hypertension Guideline
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
2017 Guideline for High Blood Pressure in Adults
Achieving the Clinical Potential of RAAS Blockade
Progress and Promise in RAAS Blockade
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Primary Hypertension Max C. Reif, M.D.
Section I: RAS manipulation
Presentation transcript:

Management of HTN in diabetic patient Fatemeh saffarian Assisstant professor of cardiology at qazvin university of medicine

HTN & DM: HTN affecting 60-70% of patients with DM. in type 2 diabetes,HTN is often present as part of the metabolic syn while in type 1,HTN may reflect the onset of diabetic nephropathy. HTN increased risk of both macrovascular & microvascular complication. People with DM & HTN have twice the risk of CVE as non-diabetic people with HTN. masked hypertension is not infrequent, so that monitoring 24-h ambulatory BP in apparently normotensive patients with diabetes,may be a useful diagnostic procedure.

Target level of BP in DM ? Which drugs prefered ? Threshold of initiation of therapy?

Hypertension Guidelines

Case A 58 year old African-American woman with diabetes and dyslipidemia has a BP of 158/94 confirmed on several office visits. Other than obesity, the exam is normal. Labs show normal renal function, well-controlled lipids on atorvastatin and well-controlled diabetes on metformin. Urine micro- albumin is mildly elevated.

Case Question 1 What goal BP is most appropriate for this patient? 1.<150/90 mmHg 2.<130/80 mmHg 3.<140/90 mmHg 4.<140/80 mmHg 5.<140/85 mmHg

Case Question 2 What is the drug of choice to start? 1.HCTZ 2.Norvasc 3.Lisinopril 4.Losartan 5.Combination therapy

Classification of BP – JNC 7 Category Systolic (mmHg) Diastolic (mmHg) Normal< 120and< 80 Pre-HTN or80-89 Hypertension Stage I or90-99 Stage II> 160or> 100

Medical Education & Information – for all Media, all Disciplines, from all over the World Powered by 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) - J Hypertension 2013;31: Definitions and classification of office BP levels (mmHg)* CategorySystolicDiastolic Optimal<120and<80 Normal120–129and/or80–84 High normal130–139and/or85–89 Grade 1 hypertension140–159and/or90–99 Grade 2 hypertension160–179and/or100–109 Grade 3 hypertension≥180and/or≥110 Isolated systolic hypertension≥140and<90 * The blood pressure (BP) category is defined by the highest level of BP, whether systolic or diastolic. Isolated systolic hypertension should be graded 1, 2, or 3 according to systolic BP values in the ranges indicated. Hypertension: SBP >140 mmHg ± DBP >90 mmHg

Definitions of hypertension by office and out-of-office blood pressure levels: Office : ≥ 140 and/ or ≥ 90 Ambulatory: Daytime (or awake): ≥135 and/or ≥85 Nighttime (or asleep): ≥120 and/or ≥70 24-h: ≥130 and/or ≥80

BP must be remeasured at least 3 times over a period of at least 4 weaks. Except: BP>180/110 or symptomatic or end organ damage

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults –JAMA. 2014;311(5): –December 18, 2013

JNC 8: Graded Recommendations A – Strong evidence B – Moderate evidence C – Weak evidence D – Against E – Expert Opinion N – No recommendation

JNC 8: Drug Treatment Thresholds and Goals Age > 60 yo –Systolic: Threshold > 150 mmHg Goal < 150 mmHg –LOE: Grade A Diastolic: Threshold > 90 mmHg Goal < 90 mmHg –LOE: Grade A

JNC 8: Drug Treatment Thresholds and Goals Age < 60 yo –Systolic: Threshold > 140 mmHg Goal < 140 mmHg Diastolic: Threshold > 90 mmHg Goal < 90 mmHg –LOE: Grade A for age 30-59; Grade E for ages For patients who can tolerate without asdverse symptom,can target as SBP<130 and DBP<80

JNC 8: Drug Treatment Thresholds and Goals Age > 18 yo with CKD or DM –JNC 7: < 130/80 (MDRD NEJM 1994) –Systolic: Threshold > 140 mmHg Goal < 140 mmHg Diastolic: Threshold > 90 mmHg Goal < 90 mmHg

For patients who can tolerate without asdverse symptom,can target as SBP<130 and DBP<80 For pts with SBP of or DBP of mmHg should initiate lifestyle modification alone,for a maximum of 3 months,if after these,BP not reduced,drug therapy initiated.

JNC 8: Initial Drug Choice Nonblack, including DM –Thiazide diuretic, CCB, ACEI, ARB LOE: Grade B Black, including DM –Thiazide diuretic, CCB LOE: Grade B (Grade C for diabetics)

JNC 8: Initial Drug Choice Age > 18 yo with CKD and HTN (regardless of race or diabetes) –Initial (or add-on) therapy should include an ACEI or ARB to improve kidney outcomes LOE: Grade B

JNC 8: Subsequent Management Reassess treatment monthly Avoid ACEI/ARB combination Consider 2-drug initial therapy for Stage 2 HTN (> 160/100) Goal BP not reached with 3 drugs, use drugs from other classes

Recent HTN Guideline Statements 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertnsion 2013;31: An Effective Approach to High Blood Pressure Control: A Science Advisory From the AHA, ACC, and CDC. Hypertension online November 15, Clinical Practice Guidelines for the Management of HTN in the Community A Statements by the ASH/ISH. J Hypertension 2014;32:3-15

Medical Education & Information – for all Media, all Disciplines, from all over the World Powered by 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) - J Hypertension 2013;31: Blood pressure goals in hypertensive patients SBP, systolic blood pressure; CV, cardiovascular; TIA, transient ischaemic attack; CHD, coronary heart disease; CKD, chronic kidney disease; DBP, diastolic blood pressure. Recommendations SBP goal for “most” Patients at low–moderate CV risk Patients with diabetes Consider with previous stroke or TIA Consider with CHD Consider with diabetic or non-diabetic CKD <140 mmHg SBP goal for elderly Ages <80 years Initial SBP ≥160 mmHg mmHg SBP goal for fit elderly Aged <80 years <140 mmHg SBP goal for elderly >80 years with SBP ≥160 mmHg mmHg DBP goal for “most”<90 mmHg DB goal for patients with diabetes<85 mmHg

BP goal in the elderly

Medical Education & Information – for all Media, all Disciplines, from all over the World Powered by 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) - J Hypertension 2013;31: RecommendationsAdditonal considerations Mandatory: initiate drug treatment in patients with SBP ≥160 mmHg Strongly recommended: start drug treatment when SBP ≥140 mmHg SBP goals for patients with diabetes: <140 mmHg DBP goals for patients with diabetes: <85 mmHg All hypertension treatment agents are recommended and may be used in patients with diabetes RAS blockers may be preferred Especially in presence of preoteinuria or microalbuminuria Choice of hypertension treatment must take comorbidities into account Coadministration of RAS blockers not recommended Avoid in patients with diabetes Hypertension treatment for people with diabetes SBP, systolic blood pressure; DBP, diastolic blood pressure; RAS, renin–angiotensin system.

Medical Education & Information – for all Media, all Disciplines, from all over the World Powered by 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) - J Hypertension 2013;31: RecommendationsAdditonal considerations Consider lowering SBP to <140 mmHg Consider BP <130/90 mmHg with overt proteinuria Monitor changes in eGFR RAS blockers more effective to reduce albuminuria than other agents Indicated in presence of microalbuminuria or overt proteinuria Combination therapy usually required to reach BP goals Combine RAS blockers with other agents Combination of two RAS blockersNot recommended Aldosterone antagonist not recommended in CKDEspecially in combination with a RAS blocker Risk of excessive reduction in renal function, hyperkalemia Hypertension treatment for people with nephropathy SBP, systolic blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; RAS, renin–angiotensin system.

Goal BP GroupBP Goal (mm Hg) GeneralDM*CKD** JNC 8:<60 yr: <140/90< 140/90 >60 yr: <150/90 ESH/ESC:< 140/90< 140/85< 140/90 Elderly /90(SBP < 130 if proteinuria) (<80 yr: SBP<140) ASH/ISH< 140/90 >80 yr: <150/90(Consider < 130/80 if proteinuria) AHA/ACC< 140/90 *ADA: < 140/80 or lower Canadian D.A:<130/80

Drug therapy of HTN in diabetes ACEI: prefered in most guidelines Favorable effects on glucose metabolism & neghropathy & CVD outcomes. In patient with H.F& post MI ACEI was superior to ARB (OPTIMAL & ELITE II trials) ARB: Similar level of recommendation in guidelines. Prefered in pts with LVH

Drug therapy of HTN in diabetes Dihydropyridine CCB : (amlodipine) Shown superiority to HCT when added to ACEI Bet a blockeres: Masking hypoglycemia symptoms Adverse effects on glucose & lipid metabolism Carvedilol prefered May be in IHD patient but no first line.

Drug therapy of HTN in diabetes Thiazide diuretics: Advers glycemic & triglyceridemic effect ALHHAT trial:compared with lisinopril & amlodipine were similar CVE effect on diabetic patients. In USA,chlorthalidone prefered(longer duration of action,more potent,

Beta-blocker / Diuretic Combination Despite trial evidence of outcome reduction, the BB / diuretic combination favours development of diabetes and should thus be avoided, unless required for other reasons,

ACEI / ARB Combination An ACEI / ARB combination presents a dubious potentiation of benefits with a consistent increase of serious side effects Specific benefits in nephropathic patients with proteinuria (because of a superior antiproteinuric effect) expect confirmation in event based trials

ACEI / CA Combination Tested or widely used combination therapy in Syst-Eur / Syst-China / HOT / ASCOT / INVEST / ACCOMPLISH Greater CV protection than placebo in Syst-Eur / Syst-China Equal (INVEST) or greater (ASCOT) CV protection than D/BB Greater CV protection than ACEI/D in ACCOMPLISH

Medical Education & Information – for all Media, all Disciplines, from all over the World Powered by 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) - J Hypertension 2013;31: Lifestyle changes for hypertensive patients * Unless contraindicated. BMI, body mass index. Recommendations to reduce BP and/or CV risk factors Salt intakeRestrict 5-6 g/day Moderate alcohol intakeLimit to g/day men, g/day women Increase vegetable, fruit, low-fat dairy intake BMI goal25 kg/m 2 Waist circumference goalMen: <102 cm (40 in.)* Women: <88 cm (34 in.)* Exercise goals≥30 min/day, 5-7 days/week (moderate, dynamic exercise) Quit smoking

Most guidelines have raised the office BP treatment threshold in DM to 140/90mmHg,except : 2013 ESH/ESC recommended 140/85 if proteinuria;130/ ADA which recommended 140/80mmHg &2013 canadian guidelines that recommended 130/80mmHg

Treatment of risk factors associated with hypertension *It is recommended to use statin in moderate to high CV risk :>40 Y or 100 (target:LDL 50,TG<150) in DM aspirin(75-162mg/day) recommended if man>50 y & woman >60 y In hypertensive patients with DM, a HbA1c target of <7.0%

Thank you for your attention